Aurinia Pharmaceuticals Inc. (AUPH)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 70,008 | 62,465 | 67,771 | 57,192 |
| Restructuring | 114 | 1,533 | - | 1,072 |
| Research and development | 7,432 | 5,743 | 3,047 | 4,080 |
| Other expense (income), net | -9,246 | -4,429 | -4,574 | 290 |
| Selling, general and administrative | 26,018 | 20,339 | 42,367 | 44,934 |
| Cost of revenue | 7,115 | 8,574 | 6,035 | 8,909 |
| Total operating expenses | 49,925 | 40,618 | 56,023 | 58,705 |
| Income (loss) from operations | 20,083 | 21,847 | 11,748 | -1,513 |
| Interest income | 3,190 | 3,569 | 4,267 | - |
| Interest expense | 1,117 | 1,067 | 1,208 | - |
| Interest expense | - | - | - | 1,198 |
| Interest income | - | - | - | 4,189 |
| Net income (loss) before income taxes | 22,156 | 24,349 | 14,807 | 1,478 |
| Income tax expense | 643 | 1,005 | 457 | 756 |
| Net income (loss) | 21,513 | 23,344 | 14,350 | 722 |
| Unrealized loss on available-for-sale securities | -80 | -178 | 474 | -5 |
| Comprehensive income (loss) | 21,433 | 23,166 | 14,824 | 717 |
| Basic (in shares) | 134,873,000 | 138,917,000 | 143,051,000 | 143,327,000 |
| Basic (in usd per share) | 0.16 | 0.17 | 0.1 | 0.01 |
| Diluted (in shares) | 137,526,000 | 143,199,000 | 145,651,000 | 144,110,000 |
| Diluted (in usd per share) | 0.16 | 0.16 | 0.1 | 0.01 |